CSP
1 min read
10

FISKARS CORPORATION: ACQUISITION OF OWN SHARES 05.12.2024

December 5, 2024
0

Reading Time: < 1 minute Stock Exchange Release 05.12.2024 at 18:30 EET/EEST   FISKARS CORPORATION: ACQUISITION OF OWN SHARES 05.12.2024   Date 05.12.2024   Exchange transaction Buy   Share class FSKRS   Amount  2,000   Average price/share 14.7420 EUR Highest price/share 14.8200 EUR Lowest price/share

Continue Reading
CSP
8 min read
11

Completed sale of shares in Eastnine AB

December 5, 2024
0

Reading Time: 6 minutes December 5, 2024 THIS PRESS RELEASE IS FOR THE USE OF THE INTENDED RECIPIENT ONLY AND SHOULD NOT BE COPIED OR DISTRIBUTED TO ANY OTHER PERSON. NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WHOLLY OR PARTLY, IN OR INTO THE U.S. (OR TO

Continue Reading
CSP
1 min read
15

Nordea Bank Abp: Repurchase of own shares on 05.12.2024

December 5, 2024
0

Reading Time: < 1 minute Nordea Bank AbpStock exchange release – Changes in company’s own shares05.12.2024 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 05.12.2024 completed repurchases of own shares (ISIN: FI4000297767) as follows: Trading venue (MIC Code) Number of shares Weighted average

Continue Reading
CSP
1 min read
32

Gentoo Media – Mandatory notification of trade

December 5, 2024
0

Reading Time: < 1 minute MJ Foundation Fundacja Rodzinna, a company related to Mateusz Juroszek, Board Member and primary insider of Gentoo Media Inc. (Gentoo) has today acquired 16,895 shares in Gentoo at a price of SEK 24.30 per share. After this transaction, close associates

Continue Reading
CSP
1 min read
11

#24-419 Delisting of Derivatives from NGM

December 5, 2024
0

Reading Time: < 1 minute Information about certain derivatives that will be delisted from NGM. For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market

Continue Reading
CSP
1 min read
8

Fondia Plc: Share repurchase 5.12.2024

December 5, 2024
0

Reading Time: < 1 minute Fondia Plc Company release 5.12.2024 at 6.45 p.m. EET   Fondia – Acquisition of own shares 5.12.2024   Fondia Plc   First North Finland   Date 5.12.2024 Exchange transactions Buy Share class FONDIA Amount, shares 977 Average price/share, EUR 4,913060

Continue Reading
CSP
4 min read
18

Pricer has successfully issued bonds of SEK 300 million and exercises its right to voluntary early redemption of its existing bonds

December 5, 2024
0

Reading Time: 3 minutes NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS, ANY STATE OF THE

Continue Reading
CSP
4 min read
99

WPTG acquires Nordic technology consultancy Nuport and resolves on a directed share issue

December 5, 2024
0

Reading Time: 3 minutes White Pearl Technology Group AB (publ) (“WPTG”) has today entered into an agreement regarding the acquisition of, and taking possession of, all shares (the “Shares”) in Nuport Sverige AB (“Nuport”). The seller of Nuport Sverige AB will receive newly issued shares in

Continue Reading
CSP
11 min read
12

Observe Medical ASA: Final result of the subsequent offering and allocation of shares; Updated amendments of loans from Navamedic ASA to be implemented including partial conversion to shares

December 5, 2024
0

Reading Time: 7 minutes NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT

Continue Reading
CSP
5 min read
11

Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease

December 5, 2024
0

Reading Time: 4 minutes Data from the trial is expected to be shared in 2025 Lund, Sweden, 5 December 2024. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA) today announced it has completed the enrolment of patients in the GOOD-IDES-02 trial, a global pivotal Phase 3 trial

Continue Reading